arXiv subjects

Ryota Ishii

Publications and source records attributed to Ryota Ishii.

6 recordsLinked to original sources

arXiv2026

Validity of MMRM-based hypothesis testing under missing-not-at-random mechanisms

In randomized clinical trials with longitudinal continuous outcomes, missing-not-at-random (MNAR) missingness often motivates conservative alternatives to mixed models for repeated measures (MMRM). Such caution is important for estimation, but estimation and testing need not require identical assumptions. Moreover, overly conservative primary analyses may reduce power, increase required sample size, and raise trial costs. We investigated the validity of MMRM-based testing under the global null of identical longitudinal outcome distributions across groups. Because valid testing minimally requires treatment-effect estimators to converge to the null under the null hypothesis, we investigated sufficient conditions for this property. We introduced a proportional observation condition requiring ratios of observation probabilities relative to a reference group, conditional on the full outcome vector, to be outcome-independent, and showed that, with arbitrary post-baseline visits and monotone missingness, this condition is sufficient for convergence to the null value. The condition allows observation to depend on unobserved outcomes and permits between-group differences in overall observation probabilities through outcome-independent dropout, making it clinically interpretable while accommodating outcome-dependent MNAR missingness. Synthetic and data-based bootstrap simulations showed negligible bias and empirical test sizes near 0.05, including nonmonotone missingness. Thus, MNAR missingness does not by itself imply that a more conservative primary testing procedure is required. This result does not justify treatment-effect estimation under alternatives, which still requires estimand-based interpretation and sensitivity analyses.

stat.ME↗

arXiv2026

A flexible framework for treatment effect inference in longitudinal clinical studies with skewed outcomes

Longitudinal continuous outcomes in clinical trials are commonly analyzed using mixed models for repeated measures (MMRM) under normality assumptions. However, many clinical outcomes are skewed, making mean-based treatment effects difficult to interpret and potentially reducing statistical efficiency. The Box--Cox MMRM (BCMMRM) approach accommodates skewness by enabling inference on model-based median differences via inverse transformation. However, BCMMRM typically assumes a common transformation parameter across treatment groups and time points. When distributional shapes differ between groups or evolve over time, this assumption may lead to biased treatment effect. Furthermore, when treatment affects not only central tendency but also distributional shape or tail behavior, treatment effects may not be adequately characterized by a single location summary such as the median. We propose the Box--Cox multivariate regression (BCMVR) framework for longitudinal data with skewed outcomes. BCMVR relaxes this restriction by allowing transformation parameters to vary across groups and time points. The framework enables inference based on interpretable summaries, including median differences and a probability-based treatment effect quantifying the probability that a randomly selected patient in one group has a better outcome than one in another group. This measure integrates information over the entire outcome distribution and provides a complementary summary when distributional shapes differ. Simulation studies demonstrate that BCMMRM can produce biased estimates when distributions differ in shape, whereas BCMVR provides nearly unbiased estimation. The probability-based measure achieves a favorable balance between robustness and statistical efficiency. The proposed framework provides a flexible and interpretable approach to treatment effect inference under distributional heterogeneity.

stat.ME↗

arXiv2026

Modification and extension of the Bayesian clinical trial design using external data for single-arm and hybrid-controlled trials

Limited patient availability complicates sample size determination in pediatric clinical trials. Although Bayesian methods incorporating external data offer a solution, rigorously controlling the type I error rate remains difficult. Psioda and Ibrahim (2019) proposed a simulation-based framework as a practical solution. However, although their framework was designed to relax the type I error control, this relaxation fails when the external data exhibit a large treatment effect, making it difficult to design clinical trials that incorporate external data. Furthermore, restricting the support of sampling priors can cause trial outcomes to fall outside of this support, leading to lower power. Additionally, their analytic prior formulation may induce bias, and their method is not applicable to hybrid-controlled trials involving two-group comparisons. Thus, we propose modifications to both the sampling and analytic prior specifications and extend the framework to hybrid-controlled trials. We redefine the null sampling prior as a normal distribution centered at the null boundary, ensuring a Bayesian type I error evaluation. For the analytic prior, we employ a weakly informative prior for the second component of a robust mixture prior to mitigate bias under prior-data conflict. Furthermore, we extend this methodology to hybrid-controlled trials. Simulation studies and a pediatric case study of cutaneous lupus erythematosus demonstrate that our method substantially reduces the required sample size compared with both frequentist and original Bayesian methods, while maintaining the target operating characteristics and controlling estimation bias under prior-data conflict. This framework provides a reliable and efficient approach for designing clinical trials that incorporate external information.

stat.ME↗

arXiv2022

Tuning of Carrier Concentration and Superconductivity in High-Entropy-Alloy-Type Metal Telluride (AgSnPbBi)(1-x)/4InxTe

High-entropy-alloy-type (HEA-type) compound superconductors have been drawing much attention as a new class of exotic superconductors with local structural inhomogeneity. NaCl-type (Ag,In,Sn,Pb,Bi)Te is a typical HEA-type superconductor, but the carrier doping mechanism had been unclear. In this study, we synthesized (Ag,In,Sn,Pb,Bi)Te with various In concentration using high-pressure synthesis: the studied system is (AgSnPbBi)(1-x)/4InxTe (x = 0-0.4). Single-phase samples were obtained for x = 0-0.3. A semiconductor-like temperature dependence of resistivity was observed for x = 0, while superconductivity appeared for the In-doped samples. The highest transition temperature (Tc) was 3.0 K for x = 0.3. The Seebeck coefficient decreases with increase of x, which suggests that In3+ generates electron carriers in (AgSnPbBi)(1-x)/4InxTe. Tuning of carrier concentration and superconducting properties of (Ag,In,Sn,Pb,Bi)Te would be useful for further investigation of exotic superconductivity in the HEA-type compound.

cond-mat.supr-con↗

arXiv2020

Confidence interval for the AUC of SROC curve and some related methods using bootstrap for meta-analysis of diagnostic accuracy studies

The area under the curve (AUC) of summary receiver operating characteristic (SROC) curve is a primary statistical outcome for meta-analysis of diagnostic test accuracy studies (DTA). However, its confidence interval has not been reported in most of DTA meta-analyses, because no certain methods and statistical packages have been provided. In this article, we provide a bootstrap algorithm for computing the confidence interval of the AUC. Also, using the bootstrap framework, we can conduct a bootstrap test for assessing significance of the difference of AUCs for multiple diagnostic tests. In addition, we provide an influence diagnostic method based on the AUC by leave-one-study-out analyses. We present illustrative examples using two DTA met-analyses for diagnostic tests of cervical cancer and asthma. We also developed an easy-to-handle R package dmetatools for these computations. The various quantitative evidence provided by these methods certainly supports the interpretations and precise evaluations of statistical evidence of DTA meta-analyses.

stat.AP↗

arXiv2019

Outlier detection and influence diagnostics in network meta-analysis

Network meta-analysis has been gaining prominence as an evidence synthesis method that enables the comprehensive synthesis and simultaneous comparison of multiple treatments. In many network meta-analyses, some of the constituent studies may have markedly different characteristics from the others, and may be influential enough to change the overall results. The inclusion of these "outlying" studies might lead to biases, yielding misleading results. In this article, we propose effective methods for detecting outlying and influential studies in a frequentist framework. In particular, we propose suitable influence measures for network meta-analysis models that involve missing outcomes and adjust the degree of freedoms appropriately. We propose three influential measures by a leave-one-trial-out cross-validation scheme: (1) comparison-specific studentized residual, (2) relative change measure for covariance matrix of the comparative effectiveness parameters, (3) relative change measure for heterogeneity covariance matrix. We also propose (4) a model-based approach using a likelihood ratio statistic by a mean-shifted outlier detection model. We illustrate the effectiveness of the proposed methods via applications to a network meta-analysis of antihypertensive drugs. Using the four proposed methods, we could detect three potential influential trials involving an obvious outlier that was retracted because of data falsifications. We also demonstrate that the overall results of comparative efficacy estimates and the ranking of drugs were altered by omitting these three influential studies.

stat.ME↗